ClinicalTrials.gg
Active, not recruitingNCT06016738OPERA-01Updated Aug 13, 2026

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

A Phase 3 interventional study of Palazestrant and Fulvestrant in Breast Cancer, Advanced Breast Cancer and Metastatic Breast Cancer, sponsored by Olema Pharmaceuticals, Inc.. Active, not recruiting at 233 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Olema Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.

Read the detailed description

This is an international, multicenter, randomized, open-label, active-controlled, phase 3 clinical trial. The purpose of this trial is to compare the safety and efficacy of palazestrant (OP-1250) as a single agent to the standard of care endocrine therapy: either fulvestrant or an aromatase inhibitor (anastrozole, letrozole, or exemestane).

This trial is seeking adult participants with ER+, HER2- advanced or metastatic breast cancer whose disease has relapsed or progressed on 1 or 2 prior lines of standard-of-care endocrine therapy for metastatic breast cancer. Prior lines of therapy must include one line of endocrine therapy in combination with a CDK 4/6 inhibitor. In the dose-selection part of the trial, approximately 120 participants will be randomized to one of the two doses of palazestrant or to the standard-of-care endocrine therapy. Thereafter, approximately 390 participants will be randomized to palazestrant at the selected dose or to the standard-of-care endocrine therapy.

02

Conditions studied

  • Breast Cancer
  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • ER Positive Breast Cancer
  • HER2 Negative Breast Carcinoma

Browse trials for

03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's planned enrollment of 510 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Olema Pharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  • Adult female or male participants.
  • ER+, - locally advanced or breast cancer that is not amenable to curative therapy.
  • Evaluable disease ( or bone-only disease).
  • Previously received a CDK4/6 inhibitor in combination with an endocrine therapy in the advanced setting. One additional line of ET as a monotherapy is allowed. Duration of the most recent prior ET must be at least 6 months.
  • (ECOG) performance status of 0 or 1.
  • Adequate hematologic, hepatic, and renal functions.
  • Female participants can be pre-, peri- or .
  • Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist.

Key exclusion criteria:

  • Symptomatic visceral disease, imminent organ failure, or any other reason that makes the participant ineligible for endocrine monotherapy.
  • Previously received chemotherapy in the advanced/metastatic setting.
  • Previously received treatment with elacestrant or an estrogen receptor-directed therapy.
  • History of allergic reactions to study treatment.
  • Any to the selected standard-of-care endocrine therapy in the local prescribing information.
  • Symptomatic central nervous system metastases, carcinomatous meningitis, , or a spinal cord compression that require immediate treatment.
  • comorbidities such as significant cardiac or cerebrovascular disease, gastrointestinal disorders that could affect absorption of study treatment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
510 participants (estimated)

Study arms

  • Experimental
    Palazestrant (OP-1250)

    Participants will receive Palazestrant

    Drug: Palazestrant

  • Active comparator
    Standard of Care Endocrine Therapy

    Participants will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)

    Drug: Fulvestrant · Drug: Anastrozole · Drug: Letrozole · Drug: Exemestane

Interventions

  • Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.

    Also known as: OP-1250

  • Participants will be treated with fulvestrant on C1D1, C1D15, and then on Day 1 of every subsequent 4 week (28 day) cycle

  • Participants will be treated with anastrozole once daily on a 4 week (28 day) cycle

  • Participants will be treated with letrozole once daily on a 4 week (28 day) cycle

  • Participants will be treated with exemestane once daily on a 4 week (28 day) cycle

06

What researchers measure

Primary outcomes

  1. Dose-Selection Part: Incidence of adverse events

    To evaluate the number of participants with adverse events

    Time frame: From Date of Randomization up to 16 weeks

  2. Dose-Selection Part: Incidence of dose reduction

    To evaluate the number of participants reducing the dose of palazestrant

    Time frame: From Date of Randomization up to 16 weeks

  3. Dose-Selection Part: Incidence of drug discontinuation

    To evaluate the number of participants discontinuing palazestrant

    Time frame: From Date of Randomization up to 16 weeks

  4. Trial: Progression-Free Survival (PFS)

    To compare PFS, based on a Blinded Independent Review Committee (BIRC) assessment, between arms of OP-1250 and standard-of-care treatment. This will be assessed separately in populations of ESR1-mutation detected and ESR1-mutation not detected participants.

    Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (estimated as up to 2 years)

Secondary outcomes

  1. Trial: Overall Survival (OS)

    To compare OS between arms of OP-1250 and standard-of-care treatment. This will be assessed separately in populations of ESR1 mutation detected and ESR1 mutation not detected participants.

    Time frame: From Date of Randomization until Death Due to Any Cause (estimated as up to 4 years)

07

Study locations

233 sites
  • Clinical Trial Site
    Tucson, Arizona 85719, United States
  • Clinical Trial Site
    Fountain Valley, California 92708, United States
  • Clinical Trial Site
    Glendale, California 91204, United States
  • Clinical Trial Site
    La Jolla, California 92093, United States
  • Clinical Trial Site
    Los Alamitos, California 90720, United States
  • Clinical Trial Site
    Los Angeles, California 90027, United States
  • Clinical Trial Site
    Whittier, California 90602, United States
  • Clinical Trial Site
    Aurora, Colorado 80045, United States
  • Clinical Trial Site
    Denver, Colorado 80218, United States
  • Clinical Trial Site
    Golden, Colorado 80401, United States
  • Clinical Trial Site
    Grand Junction, Colorado 81505, United States
  • Clinical Trial Site
    Danbury, Connecticut 06810, United States
  • Clinical Trial Site
    Newark, Delaware 19713, United States
  • Clinical Trials Site
    Jacksonville, Florida 32223, United States
  • Clinical Trial Site
    Margate, Florida 33063, United States
  • Clinical Trial Site
    Orlando, Florida 32804, United States
  • Clinical Trial Site
    Plantation, Florida 33324, United States
  • Clinical Trial Site
    Tamarac, Florida 33321, United States
  • Clinical Trial Site
    Atlanta, Georgia 30322, United States
  • Clinical Trial Site
    Chicago, Illinois 60616-2315, United States
  • Clinical Trial Site
    Chicago, Illinois 60637, United States
  • Clinical Trial Site
    Urbana, Illinois 61801, United States
  • Clinical Trial Site
    Baton Rouge, Louisiana 70809, United States
  • Clinical Trial Site
    New Orleans, Louisiana 70112, United States
  • Clinical Trial Site
    Baltimore, Maryland 21201, United States
  • Clinical Trial Site
    Boston, Massachusetts 02111, United States
  • Clinical Trial Site
    Detroit, Michigan 48202, United States
  • Clinical Trial Site
    Saint Louis Park, Minnesota 55426, United States
  • Clinical Trial Site
    Woodbury, Minnesota 55125, United States
  • Clinical Trial Site
    Lincoln, Nebraska 68516, United States
  • Clinical Trial Site
    Farmington, New Mexico 87401, United States
  • Clinical Trial Site
    New York, New York 10032, United States
  • Clinical Trial Site
    Port Jefferson Station, New York 11776, United States
  • Clinical Trial Site
    Dayton, Ohio 45415, United States
  • Clinical Trial Site
    Toledo, Ohio 43623, United States
  • Clinical Trial Site
    Portland, Oregon 97239, United States
  • Clinical Trial Site
    Sayre, Pennsylvania 18840, United States
  • Clinical Trial Site
    Nashville, Tennessee 37203, United States
  • Clinical Trial Site
    Nashville, Tennessee 37208, United States
  • Clinical Trial Site
    Nashville, Tennessee 37232, United States
  • Clinical Trial Site
    Dallas, Texas 75246, United States
  • Clinical Trial Site
    Dallas, Texas 75390, United States
  • Clinical Trial Site
    Houston, Texas 77054, United States
  • Clinical Trial Site
    Webster, Texas 77598, United States
  • Clinical Trial Site
    Ogden, Utah 84405, United States
  • Clinical Trial Site
    Spokane, Washington 99204, United States
  • Clinical Trial Site
    Spokane, Washington 99208, United States
  • Clinical Trial Site
    Bahía Blanca, Buenos Aires B8000HXM, Argentina
  • Clinical Trial Site
    Mar del Plata, Buenos Aires B7600FZN, Argentina
  • Clinical Trial Site
    Mar del Plata, Buenos Aires, Argentina
  • Clinical Trial Site
    Córdoba, Córdoba Province X5000HHW, Argentina
  • Clinical Trial Site
    Córdoba, Córdoba Province X5008HHW, Argentina
  • Clinical Trial Site
    San Salvador de Jujuy, Jujuy Province 4600, Argentina
  • Clinical Trial Site
    La Rioja, La Rioja Province 5300, Argentina
  • Clinical Trial Site
    Viedma, Río Negro Province R8500ACE, Argentina
  • Clinical Trial Site
    Rosario, Santa Fe Province S2013DTC, Argentina
  • Clinical Trial Site
    Rosario, Santa Fe Province S2013KDS, Argentina
  • Clinical Trial Site
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Clinical Trial Site
    Buenos Aires, C14626ABP, Argentina
  • Clinical Trial Site
    Gosford, New South Wales 2250, Australia
  • Clinical Trial Site
    Westmead, New South Wales 2145, Australia
  • Clinical Trial Site
    Adelaide, South Australia 5000, Australia
  • Clinical Trial Site
    Ballarat Central, Victoria 3355, Australia
  • Clinical Trial Site
    Clayton, Victoria 3168, Australia
  • Clinical Trial Site
    Shepparton, Victoria 3630, Australia
  • Clinical Trial Site
    Nedlands, Western Australia 6009, Australia
  • Clinical Trial Site
    Wels, 4600, Austria
  • Clinical Trial Site
    Wiener Neustadt, 2700, Austria
  • Clinical Trial Site
    Edegem, Antwerpen 2650, Belgium
  • Clinical Trial Site
    Wilrijk, Antwerpen 2610, Belgium
  • Clinical Trial Site
    Woluwe-Saint-Lambert, Brussels Capital 1200, Belgium
  • Clinical Trial Site
    Charleroi, Hainaut 6060, Belgium
  • Clinical Trial Site
    Leuven, Vlaams Brabant, Belgium
  • Clinical Trial Site
    Salvador, Estado de Bahia 41253-190, Brazil
  • Clinical Trial Site
    Brasília, Federal District 70.390-140, Brazil
  • Clinical Trial Site
    São Luís, Maranhão 65.060-645, Brazil
  • Clinical Trial Site
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • Clinical Trial Site
    Curitiba, Paraná 81520-060, Brazil
  • Clinical Trial Site
    Recife, Pernambuco 50070-480, Brazil
  • Clinical Trial Site
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Clinical Trial Site
    Porto Alegre, Rio Grande do Sul 90050-170, Brazil
  • Clinical Trial Site
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Clinical Trial Site
    Itajaí, Santa Catarina 88301-220, Brazil
  • Clinical Trial Site
    Jaú, São Paulo 17210-080, Brazil
  • Clinical Trial Site
    Sorocaba, São Paulo 18052-775, Brazil
  • Clinical Trial Site
    Porto Alegre, 90470-340, Brazil
  • Clinical Trial Site
    Rio de Janeiro, 22281-100, Brazil
  • Clinical Trial Site
    Panagyurishte, Pazardzhik 4500, Bulgaria
  • Clinical Trial Site
    Sofia, Sofia-Grad 1407, Bulgaria
  • Clinical Trial Site
    Vratsa, Vratsa 3000, Bulgaria
  • Clinical Trial Site
    Calgary, Alberta T2N 5G2, Canada
  • Clinical Trial Site
    London, Ontario N6A 5W9, Canada
  • Clinical Trial Site
    Toronto, Ontario M5G 1X5, Canada
  • Clinical Trial Site
    Montreal, Quebec H4A 3J1, Canada
  • Clinical Trial Site
    Hradec Králové, Hradec Králové Region 500 12, Czechia
  • Clinical Trial Site
    Nový Jičín, Moravian-Silesian Region 741 01, Czechia
  • Clinical Trial Site
    Olomouc, Olomouc Region 779 00, Czechia
  • Clinical Trial Site
    Brno, 625 00, Czechia
  • Clinical Trial Site
    Prague, 140 59, Czechia
  • Clinical Trial Site
    Bourg-en-Bresse, Ain 01000, France

Showing the first 100 of 233 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Pistilli B, Bellet Ezquerra M, Del Mastro L, Sohn J, Schmid P, Meisel J, Chan A, Zheng L, de Kermadec E, McArthur H. OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy. Future Oncol. 2026 Jan;22(2):157-166. doi: 10.1080/14796694.2025.2608863. Epub 2025 Dec 29. PubMed 41461598 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Oct 2026, 35 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 35 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Aug 30, 2023
StartActual
Nov 16, 2023
Primary completionEst.
Oct 31, 2026
CompletionEst.
Feb 29, 2028
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06016738
Lead sponsor
Olema Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 30, 2023
Start date
Nov 16, 2023
Primary completion
Oct 31, 2026 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Aug 13, 2026

Study contacts

Medical Director, MD
study director · Olema Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palazestrant

Start the discussion